Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BB4 antibody + iodine 131
- Development stage
- Phase 1
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BB4 antibody + iodine 131 is a radioimmunoconjugate composed of the monoclonal antibody BB4 (which targets syndecan-1/CD138) conjugated to the radioactive isotope iodine-131. The combination is designed for radioimmunotherapy of cancers expressing high levels of CD138/syndecan-1, such as multiple myeloma and certain breast cancers. The mechanism involves the specific binding of the BB4 monoclonal antibody to CD138 on tumor cells; once bound, the attached radioactive iodine delivers localized radiation to kill cancer cells while sparing most normal tissues. Preclinical and early clinical studies have shown promising antitumor activity and manageable toxicity profiles in models of multiple myeloma and breast cancer[1][2][3].
- Other names
- anti-CD138 antibody BB4 labeled with iodine-131anti-CD-138 antibody BB4 labeled with iodine-131anti-CD 138 antibody BB4 labeled with iodine-131131I-labeled anti-CD138 monoclonal antibody (BB4)radioimmunoconjugate BB4-I-131
02
Targets
SDC1 (Syndecan-1)
Beyond the preview
Go deeper on BB4 antibody + iodine 131.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BB4 antibody + iodine 131.